NCT06894212: An ongoing trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial is ongoing. It must report results 1 year, 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06894212 |
|---|---|
| Title | A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 28, 2025 |
| Completion date | Oct. 20, 2026 |
| Required reporting date | Oct. 20, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |